ID   EW-16
AC   CVCL_1212
SY   EW16; IARC-EW16; IARC-EW-16; IARC-EW 16
DR   CLO; CLO_0009869
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 883
DR   cancercelllines; CVCL_1212
DR   Cell_Model_Passport; SIDM00198
DR   ChEMBL-Cells; CHEMBL3308195
DR   ChEMBL-Targets; CHEMBL2366358
DR   Cosmic; 684065
DR   Cosmic; 949165
DR   Cosmic; 1995401
DR   Cosmic; 2250472
DR   Cosmic-CLP; 949165
DR   DepMap; ACH-002114
DR   EGA; EGAS00001000978
DR   GDSC; 949165
DR   GEO; GSM1669785
DR   IARC_TP53; 27165
DR   LINCS_LDP; LCL-1449
DR   PharmacoDB; EW16_354_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1212
DR   Wikidata; Q54832993
RX   DOI=10.5282/edoc.27750;
RX   PubMed=11423975;
RX   PubMed=20164919;
RX   PubMed=25223734;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=25223734).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=EWSR1 exon 8 fused to FLI1 exon 7 (PubMed=11423975).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys120Serfs*3 (c.359delA); Zygosity=Heterozygous (PubMed=25223734; Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.19%; Native American=1.1%; East Asian, North=0%; East Asian, South=0.45%; South Asian=0.79%; European, North=55.49%; European, South=41.99% (PubMed=30894373).
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D13S317: 12,14
ST   D16S539: 13
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   TH01: 9,9.3
ST   TPOX: 8,9
ST   vWA: 17,19
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 32
//
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021), Ludwig Maximilians University of Munich, Germany.
//
RX   PubMed=11423975; DOI=10.1038/sj.onc.1204437;
RA   Dauphinot L., De Oliveira C., Melot T., Sevenet N., Thomas V.,
RA   Weissman B.E., Delattre O.;
RT   "Analysis of the expression of cell cycle regulators in Ewing cell
RT   lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression.";
RL   Oncogene 20:3258-3265(2001).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622;
RA   Tirode F., Surdez D., Ma X.-T., Parker M., Le Deley M.-C., Bahrami A.,
RA   Zhang Z.-J., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S.,
RA   Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O.,
RA   Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M.,
RA   Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V.,
RA   Michon J., Marec-Berard P., Gut I.G., Downing J.R., Dyer M.A.,
RA   Zhang J.-H., Delattre O.;
RT   "Genomic landscape of Ewing sarcoma defines an aggressive subtype with
RT   co-association of STAG2 and TP53 mutations.";
RL   Cancer Discov. 4:1342-1353(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//